Business Wire

Morgan Stanley Expands Global Inclusive Ventures Lab with Largest Single Cohort of 23 Companies

12.9.2023 15:00:00 EEST | Business Wire | Press release

Share

Morgan Stanley (NYSE: MS) today announced the 2023 global cohort of the Inclusive Ventures Lab, with 23 companies selected across North America and Europe, the Middle East and Africa (EMEA), double the size of previous cohorts. The Lab offers a five-month in-house accelerator program for underrepresented founders of technology and technology-enabled startups in the post-seed to Series A funding round stage.

Chosen from over 7,900 applicants – more than three times last year’s pool – the selected startups represent a range of disruptive technologies in industries including healthcare, sustainable solutions, customer service, supply chain, recruiting and cybersecurity. Companies in the cohort receive a $250,000 investment (£250,000 in EMEA) from Morgan Stanley, as well as a variety of mentorship opportunities and business-growth resources from Morgan Stanley’s ecosystem of internal and external partners.

“We are proud to welcome the Lab’s largest cohort yet, marking our continued efforts to create a more equitable investment landscape for overlooked entrepreneurs worldwide,” said Selma Bueno, Global Head of the Morgan Stanley Inclusive Ventures Group. “We are working to bridge the investment gap for underserved founders and to help correct documented market imbalances.”

The selected companies in the 2023 global cohort include the following:

  • Ad Auris empowers marketing teams, publishers and content creators to repurpose written content into high-quality audio to reach an audience of listeners (Canada)
  • Automated Architecture provides the technological infrastructure for a distributed robotic micro-factory network producing sustainable timber housing (UK)
  • Bidrento offers an all-in-one solution for tenant experience and rental property management, helping to save time and money while also reducing CO2 emissions in real estate (Estonia)
  • ByFusion provides a zero waste landfill diversion platform to transform non-recyclable plastic waste into reusable building materials (US)
  • Cult Mia is an online fashion marketplace for sustainable and ethical brands from around the world (UK)
  • DotLab develops breakthrough, actionable AI and ML technologies that lead to better health outcomes for women, starting with the diagnosis of endometriosis (US)
  • eBanqo offers businesses an omnichannel platform to drive customer engagement and support (Nigeria)
  • Encounter AI uses digital conversational ordering solutions to provide faster, friendlier and more efficient service to customers, restaurants and retailers (US)
  • FLUIX Inc. enterprise AI software saves critical infrastructure on energy costs by integrating and optimizing facility systems (US)
  • GigBridge is an online platform for construction companies to hire, onboard and pay their workforce all in one place (UK)
  • Health in Her HUE connects Black women and women of color to culturally sensitive healthcare providers, health content and community support through a digital platform (US)
  • Inicio AI delivers a virtually guided affordability assessment to help organizations save contact center costs while improving their end customer experience (UK)
  • MEDIjobs is the first virtual recruiter for the healthcare industry, filling more than 55 types of positions at a rate five times faster than a human would (US)
  • Nopalera is a collection of bath and body products powered by Mexico’s nopal cactus – an ancient symbol of Mexican culture (US)
  • OKO offers affordable and inclusive crop insurance to farmers in emerging countries using satellite weather data and mobile payment technologies (Israel)
  • Oppos provides robust cybersecurity and compliance security solutions for businesses, safeguarding data confidentiality, integrity, and availability (Canada)
  • Partsimony enables organizations to build intelligent manufacturing supply chains that are more resilient and sustainable by unifying engineering and supply chain data (US)
  • Ridelink leverages technology to enable small and medium-sized businesses to move cargo in Uganda and cross-border in six neighboring countries (Uganda)
  • serviceMob is an AI & ML-powered customer service analytics platform that helps businesses optimize operations and improve the customer experience (US)
  • Stak Mobility facilitates widespread urban electric vehicle adoption by merging space-saving vertical parking automation with fully integrated EV charging and a seamless mobile self-service experience (US)
  • Tall Poppy is a digital security company protecting employees and public facing teams from online threats (US)
  • Twipes uses bio-tech to produce flushable, biodegradable wet wipes that break down in water in three hours and biodegrade in landfills in seven days (US)
  • Unfabled is a consumer health platform that delivers personalized solutions for women by matching them with health and wellness products (UK)

“We are thrilled to bring our unique accelerator program to more entrepreneurs globally, including our first participants from Africa and the Middle East,” said Sanghamitra Karra, EMEA Head of the Inclusive Ventures Group. “It is highly rewarding to work closely with founders to take their game-changing technologies to scale and help set them up for continued success.”

“By providing these promising startups with much-needed capital, a tailored curriculum and access to investors within and beyond the Firm’s far-reaching network, we aim to ensure that more underrepresented founders can succeed,” said LaToya Wilson, Americas Head of the Inclusive Ventures Group.

Programming will run through February 2024 and culminate in a global Demo Day, when participating companies will present to potential investors, business partners and customers.

The Inclusive Ventures Lab has won multiple Gold Anthem Awards, including Most Impactful Corporate Initiative in 2022 and Corporate Social Responsibility in 2023. The program was also listed as one of Global Finance’s Best Innovation Labs of 2023.

About the Morgan Stanley Inclusive Ventures Lab

The Morgan Stanley Inclusive Ventures Lab (MSIVL) is an intensive five-month in-house accelerator program designed to help further develop and scale startups, culminating in a showcase presentation and Demo Day to the investor community. Morgan Stanley launched MSIVL, formerly called the Multicultural Innovation Lab, in 2017 in order to address inequities in funding of underrepresented founders, which our research shows equals over four trillion dollars in unrealized returns.

About Morgan Stanley

Morgan Stanley (NYSE: MS) is a leading global financial services firm providing a wide range of investment banking, securities, wealth management and investment management services. With offices in 42 countries, the Firm’s employees serve clients worldwide including corporations, governments, institutions and individuals. For further information about Morgan Stanley, please visit www.morganstanley.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Relations: Carrie Hall, carrie.hall@morganstanley.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye